Evotec Announces Chief Scientific Officer Transition
Evotec SE announced that Chief Scientific Officer Dr. Cord Dohrmann will step down from his position effective September 30, 2026. The decision was made by mutual consent between Dr. Dohrmann and the company.
Drug discovery and development company Evotec SE has announced that its Chief Scientific Officer (CSO), Dr. Cord Dohrmann, will step down from his role effective September 30, 2026. The decision for Dr. Dohrmann to depart was made through mutual agreement with the company.
Dr. Dohrmann has served as CSO and a member of the Management Board since 2010, accumulating 16 years of service with Evotec. Evotec CEO Christian Wojczewski expressed gratitude for Dr. Dohrmann's long tenure and significant contributions, highlighting his role in strengthening the company's scientific excellence and innovation culture.
Wojczewski stated that Dr. Dohrmann's strategic vision has been instrumental in developing key capabilities, including iPSC-based technologies and omics expertise, which have bolstered Evotec's scientific leadership. The company indicated that the robust scientific infrastructure built under Dr. Dohrmann's guidance will be essential for Evotec's future growth and profitability.
Dr. Dohrmann commented that the process of advancing new therapies from discovery to the clinic has evolved substantially during his time at Evotec. He conveyed his appreciation for his colleagues and expressed anticipation for Evotec's scientific expertise to continue creating value for customers, partners, and patients.
Evotec SE is currently conducting a search for Dr. Dohrmann's successor. The company focuses on drug discovery and development, leveraging AI and advanced technologies.